Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer

• DOI: 10.1016/j.adro.2024.101507
• Publication Date: 2024-04-13T02:26:06Z
• Authors: Philip Sutera; Matthew P. Deek; Rebecca A. Deek; Ozan Cem Guler; Pervin Hurmuz; Mehmet Reyhan; Steven Rowe; Noura Radwan; Shirl Dipasquale; William T. Hrinivich; Kathryn Lowe; Lei Ren; Biren Saraiya; Ronald Ennis; Lara Hathout; Tina Mayer; Theodore L. Deweese; Daniel Y. Song; Ana Kiess; Ezgi Oymak; Kenneth Pienta; Felix Feng; Martin Pomper; Gokhan Ozyigit; Phuoc T. Tran; Cem Onal; Ryan M. Phillips
• Keywords: Ablative case

Emerging data suggest that metastasis-directed therapy (MDT) improves outcomes in patients with oligometastatic castration-sensitive prostate cancer (omCSPC). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) can detect occult metastatic disease, and PSMA response has been proposed as a biomarker for treatment response. Herein, we identify validate PSMA-PET metastasis-free survival (MFS) following MDT omCSPC.